Pharmaceutical company Endo Inc (OTCQX: NDOI) announced Thursday the launch of ADRENALIN (epinephrine in 0.9% sodium chloride injection) 8 mg/250 mL premixed bag, and will begin distribution from the week of 19 May 2025.

ADRENALIN is the first FDA-approved and currently only manufacturer-prepared epinephrine premixed IV bag on the market.

The ready-to-use product streamlines hospital operations by eliminating the need to prepare or transfer the product before patient administration, Endo said.

In addition, Endo offers ADRENALIN 4 mg/250 mL premixed bag and plans to launch 5 mg/250 mL and 10 mg/250 mL concentrations. The company also offers ADRENALIN (epinephrine injection, USP) 1 mL single-dose and 30 mL multi-dose vials.

ADRENALIN increases mean arterial blood pressure in adult patients with hypotension associated with septic shock.